Cargando…
Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy
Deficits in plasma membrane repair have been identified in dysferlinopathy and Duchenne Muscular Dystrophy, and contribute to progressive myopathy. Although Facioscapulohumeral Muscular Dystrophy (FSHD) shares clinicopathological features with these muscular dystrophies, it is unknown if FSHD is cha...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432481/ https://www.ncbi.nlm.nih.gov/pubmed/32759720 http://dx.doi.org/10.3390/ijms21155575 |
_version_ | 1783571808389169152 |
---|---|
author | Bittel, Adam J. Sreetama, Sen Chandra Bittel, Daniel C. Horn, Adam Novak, James S. Yokota, Toshifumi Zhang, Aiping Maruyama, Rika Rowel Q. Lim, Kenji Jaiswal, Jyoti K. Chen, Yi-Wen |
author_facet | Bittel, Adam J. Sreetama, Sen Chandra Bittel, Daniel C. Horn, Adam Novak, James S. Yokota, Toshifumi Zhang, Aiping Maruyama, Rika Rowel Q. Lim, Kenji Jaiswal, Jyoti K. Chen, Yi-Wen |
author_sort | Bittel, Adam J. |
collection | PubMed |
description | Deficits in plasma membrane repair have been identified in dysferlinopathy and Duchenne Muscular Dystrophy, and contribute to progressive myopathy. Although Facioscapulohumeral Muscular Dystrophy (FSHD) shares clinicopathological features with these muscular dystrophies, it is unknown if FSHD is characterized by plasma membrane repair deficits. Therefore, we exposed immortalized human FSHD myoblasts, immortalized myoblasts from unaffected siblings, and myofibers from a murine model of FSHD (FLExDUX4) to focal, pulsed laser ablation of the sarcolemma. Repair kinetics and success were determined from the accumulation of intracellular FM1-43 dye post-injury. We subsequently treated FSHD myoblasts with a DUX4-targeting antisense oligonucleotide (AON) to reduce DUX4 expression, and with the antioxidant Trolox to determine the role of DUX4 expression and oxidative stress in membrane repair. Compared to unaffected myoblasts, FSHD myoblasts demonstrate poor repair and a greater percentage of cells that failed to repair, which was mitigated by AON and Trolox treatments. Similar repair deficits were identified in FLExDUX4 myofibers. This is the first study to identify plasma membrane repair deficits in myoblasts from individuals with FSHD, and in myofibers from a murine model of FSHD. Our results suggest that DUX4 expression and oxidative stress may be important targets for future membrane-repair therapies. |
format | Online Article Text |
id | pubmed-7432481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74324812020-08-24 Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy Bittel, Adam J. Sreetama, Sen Chandra Bittel, Daniel C. Horn, Adam Novak, James S. Yokota, Toshifumi Zhang, Aiping Maruyama, Rika Rowel Q. Lim, Kenji Jaiswal, Jyoti K. Chen, Yi-Wen Int J Mol Sci Article Deficits in plasma membrane repair have been identified in dysferlinopathy and Duchenne Muscular Dystrophy, and contribute to progressive myopathy. Although Facioscapulohumeral Muscular Dystrophy (FSHD) shares clinicopathological features with these muscular dystrophies, it is unknown if FSHD is characterized by plasma membrane repair deficits. Therefore, we exposed immortalized human FSHD myoblasts, immortalized myoblasts from unaffected siblings, and myofibers from a murine model of FSHD (FLExDUX4) to focal, pulsed laser ablation of the sarcolemma. Repair kinetics and success were determined from the accumulation of intracellular FM1-43 dye post-injury. We subsequently treated FSHD myoblasts with a DUX4-targeting antisense oligonucleotide (AON) to reduce DUX4 expression, and with the antioxidant Trolox to determine the role of DUX4 expression and oxidative stress in membrane repair. Compared to unaffected myoblasts, FSHD myoblasts demonstrate poor repair and a greater percentage of cells that failed to repair, which was mitigated by AON and Trolox treatments. Similar repair deficits were identified in FLExDUX4 myofibers. This is the first study to identify plasma membrane repair deficits in myoblasts from individuals with FSHD, and in myofibers from a murine model of FSHD. Our results suggest that DUX4 expression and oxidative stress may be important targets for future membrane-repair therapies. MDPI 2020-08-04 /pmc/articles/PMC7432481/ /pubmed/32759720 http://dx.doi.org/10.3390/ijms21155575 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bittel, Adam J. Sreetama, Sen Chandra Bittel, Daniel C. Horn, Adam Novak, James S. Yokota, Toshifumi Zhang, Aiping Maruyama, Rika Rowel Q. Lim, Kenji Jaiswal, Jyoti K. Chen, Yi-Wen Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy |
title | Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy |
title_full | Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy |
title_fullStr | Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy |
title_full_unstemmed | Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy |
title_short | Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy |
title_sort | membrane repair deficit in facioscapulohumeral muscular dystrophy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432481/ https://www.ncbi.nlm.nih.gov/pubmed/32759720 http://dx.doi.org/10.3390/ijms21155575 |
work_keys_str_mv | AT bitteladamj membranerepairdeficitinfacioscapulohumeralmusculardystrophy AT sreetamasenchandra membranerepairdeficitinfacioscapulohumeralmusculardystrophy AT bitteldanielc membranerepairdeficitinfacioscapulohumeralmusculardystrophy AT hornadam membranerepairdeficitinfacioscapulohumeralmusculardystrophy AT novakjamess membranerepairdeficitinfacioscapulohumeralmusculardystrophy AT yokotatoshifumi membranerepairdeficitinfacioscapulohumeralmusculardystrophy AT zhangaiping membranerepairdeficitinfacioscapulohumeralmusculardystrophy AT maruyamarika membranerepairdeficitinfacioscapulohumeralmusculardystrophy AT rowelqlimkenji membranerepairdeficitinfacioscapulohumeralmusculardystrophy AT jaiswaljyotik membranerepairdeficitinfacioscapulohumeralmusculardystrophy AT chenyiwen membranerepairdeficitinfacioscapulohumeralmusculardystrophy |